Literature DB >> 17595250

Plasma osteopontin levels and expression in adipose tissue are increased in obesity.

Javier Gómez-Ambrosi1, Victoria Catalán, Beatriz Ramírez, Amaia Rodríguez, Inmaculada Colina, Camilo Silva, Fernando Rotellar, Carmen Mugueta, María J Gil, Javier A Cienfuegos, Javier Salvador, Gema Frühbeck.   

Abstract

CONTEXT: Obesity acts as a cardiovascular risk factor by mechanisms that are not fully understood. Osteopontin (OPN) is a proinflammatory mediator involved in tissue remodeling that plays a role in atherosclerosis and diabetes.
OBJECTIVE: The aim of the present study was to compare the circulating concentrations of OPN and its mRNA expression in omental adipose tissue of lean, overweight, and obese individuals and to analyze the effect of weight loss. SUBJECTS AND METHODS: Plasma concentrations of OPN were measured in 77 volunteers. OPN mRNA expression in omental adipose tissue obtained from 12 women was quantified by real-time PCR. In addition, the concentrations of OPN in 12 obese men were measured before and after weight loss following a dietetic program.
SETTING: The study was conducted at a University Hospital.
RESULTS: Obese and overweight patients exhibited significantly increased circulating OPN concentrations as compared with lean subjects (obese 72.6 +/- 28.5, overweight 68.2 +/- 20.8, lean 42.7 +/- 27.9 ng/ml; P < 0.001). A significant positive correlation was found between OPN levels and body fat (r = 0.45; P < 0.0001). Obese individuals showed significantly increased (P < 0.05) mRNA expression of OPN in omental adipose tissue as compared with lean volunteers, which was further increased in obese diabetic patients. Diet-induced weight loss significantly decreased OPN concentrations from 64.7 +/- 22.1 to 36.6 +/- 20.1 ng/ml (P = 0.006).
CONCLUSIONS: These findings represent the first observation that plasma OPN and mRNA expression of OPN in omental adipose tissue are increased in overweight/obese patients with the latter being further elevated in obesity-associated diabetes. Moreover, weight loss reduces OPN concentrations, which may contribute to the beneficial effects accompanying weight reduction. Measurement of OPN might be useful for evaluating the outcomes of various clinical interventions for obesity-related cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17595250     DOI: 10.1210/jc.2007-0349

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  82 in total

1.  Effect of sleeve gastrectomy on osteopontin circulating levels and expression in adipose tissue and liver in rats.

Authors:  Andoni Lancha; Rafael Moncada; Víctor Valentí; Amaia Rodríguez; Victoria Catalán; Sara Becerril; Beatriz Ramírez; Leire Méndez-Giménez; Gema Frühbeck; Javier Gómez-Ambrosi
Journal:  Obes Surg       Date:  2014-10       Impact factor: 4.129

2.  Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis.

Authors:  Hye-In Ji; Sang-Hoon Lee; Ran Song; Hyung-In Yang; Yeon-Ah Lee; Seung-Jae Hong; Somi Kim; Yong-Beom Park; Soo-Kon Lee; Myung Chul Yoo; Kyoung Soo Kim
Journal:  Clin Rheumatol       Date:  2013-09-01       Impact factor: 2.980

Review 3.  The bone-adipose axis in obesity and weight loss.

Authors:  J Gómez-Ambrosi; A Rodríguez; V Catalán; G Frühbeck
Journal:  Obes Surg       Date:  2008-06-19       Impact factor: 4.129

4.  Monocyte chemoattractant protein-1 deficiency protects against visceral fat-induced atherosclerosis.

Authors:  Miina K Ohman; Andrew P Wright; Kevin J Wickenheiser; Wei Luo; Hana M Russo; Daniel T Eitzman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-03-18       Impact factor: 8.311

5.  Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients.

Authors:  J M Gallego-Escuredo; J Gómez-Ambrosi; V Catalan; P Domingo; M Giralt; G Frühbeck; F Villarroya
Journal:  Int J Obes (Lond)       Date:  2014-05-12       Impact factor: 5.095

6.  Adipocyte-mononuclear cell interaction, Toll-like receptor 4 activation, and high glucose synergistically up-regulate osteopontin expression via an interleukin 6-mediated mechanism.

Authors:  Devadoss J Samuvel; Kamala P Sundararaj; Yanchun Li; Maria F Lopes-Virella; Yan Huang
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

7.  Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance.

Authors:  Georg Schaller; Yoshimasa Aso; Gerit-Holger Schernthaner; Hans-Peter Kopp; Toshihiko Inukai; Stefan Kriwanek; Guntram Schernthaner
Journal:  Obes Surg       Date:  2008-05-02       Impact factor: 4.129

8.  Differential effects of high-fat-diet rich in lard oil or soybean oil on osteopontin expression and inflammation of adipose tissue in diet-induced obese rats.

Authors:  Xiaoke Wang; Mengjie Cheng; Min Zhao; Aiguo Ge; Fangfang Guo; Min Zhang; Yanhong Yang; Liegang Liu; Nianhong Yang
Journal:  Eur J Nutr       Date:  2012-07-31       Impact factor: 5.614

9.  Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity.

Authors:  Adeline Bertola; Vanessa Deveaux; Stéphanie Bonnafous; Déborah Rousseau; Rodolphe Anty; Abdelilah Wakkach; Moncef Dahman; Joan Tordjman; Karine Clément; Siobhán E McQuaid; Keith N Frayn; Pierre-Michel Huet; Jean Gugenheim; Sophie Lotersztajn; Yannick Le Marchand-Brustel; Albert Tran; Philippe Gual
Journal:  Diabetes       Date:  2008-10-24       Impact factor: 9.461

10.  Genes and gene expression modules associated with caloric restriction and aging in the laboratory mouse.

Authors:  William R Swindell
Journal:  BMC Genomics       Date:  2009-12-07       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.